title: Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
abstract: OBJECTIVE
  In polycythaemia vera (PV) and essential thrombocythaemia (ET), the life expectancy of the patients is greatly affected by thrombotic events. An investigation was performed of the potential association of PV/ET, and thrombotic complications with cardiovascular (CV) risk factors, a leukocyte count at the haematological diagnosis > 11.1 G/L, and the JAK2V617F mutation.
  
  
  METHODS
  In the period 1998-2011, 128 women with a median age of 62 years were enrolled.
  
  
  RESULTS
  The risk of thrombotic events before the diagnosis was 32.8% (42/128), while in the follow-up period it was 10.2% (13/128). The difference in the probability of thrombosis-free survival between those with at most one CV risk factor and those with two or more CV risk factors was significant (p = 0.005). The presence of two or more CV risk factors (univariate: p = 0.011; multivariate: relative risk: 4.728, 95% CI 1.312-17.040; p = 0.018) significantly increased the risk of thrombosis. Univariate analyses revealed that high blood pressure (p = 0.001), hyperlipidaemia (p = 0.005) and cigarette smoking (p = 0.051) were associated with a significantly higher risk of thrombosis. Analyses of the influence of the leukocyte count (univariate: p = 0.424; multivariate: relative risk: 1.407, 95% CI 0.359-5.507; p = 0.624) and the JAK2V617F mutation (univariate: p = 0.367; multivariate: relative risk: 1.428, 95% CI 0.316-6.460; p = 0.643) on subsequent thrombotic complications resulted in a non-signicant tendency.
  
  
  CONCLUSIONS
  Female patients who display CV risk factors (high blood pressure, hyperlipidaemia and/or cigarette smoking) and PV or ET may well be at a higher risk of thrombotic events and require special consideration as concerns as the prevention and management of thrombotic events.
authors.affiliation: 2nd Department of Internal Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Hungary. evaposfay@gmail.com.
authors.forename: É
authors.initials: É
authors.lastname: Pósfai
authors.forename: I
authors.initials: I
authors.lastname: Marton
authors.forename: Z
authors.initials: Z
authors.lastname: Kiss-László
authors.forename: B
authors.initials: B
authors.lastname: Kotosz
authors.forename: M
authors.initials: M
authors.lastname: Széll
authors.forename: Z
authors.initials: Z
authors.lastname: Borbényi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology; D011087:Polycythemia Vera / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D013920:Thrombocythemia, Essential / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D019851:Thrombophilia / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D055815:Young Adult